Clinical value of combined detection of cytokeratin 19 and polymorphic epithelial mucin in peripheral blood of patients with thyroid cancer / 肿瘤
Qin-Jiang LIU.
Tumor
; (12): 929-934, 2014.
Artículo
en Zh
| WPRIM | ID: wpr-848880
Objective:
To examine the expressions of cytokeratin 19 (CK19) and polymorphic epithelial mucin (MUC1) in peripheral blood of patients with thyroid cancer, and evaluate their clinical value as the biomarkers in the detection of circulating tumor cells and blood micrometastasis.Methods:
The flow cytometry (FCM) was used to detect CK19-positive and MUC1-positive cells in peripheral blood of 491 patients with thyroid cancer and 376 patients with nodular goiter.Results:
The positive expression rates of CK19 in patients with thyroid cancer and nodular goiter were 35.4% (174/491) and 7.7% (29/376), respectively (P = 0.000); the positive expression rates of MUC1 in patients with thyroid cancer and nodular goiter were 32.8% (161/491) and 3.5% (13/376), respectively (P = 0.000). In univariate analysis, the tumor size, tumor capsule invasion, lymph node metastasis and distant metastasis were significantly associated with the positive expression of CK19 or MUC1 and the positive expressions of both CK19 and MUC1 (P < 0.05). In multivariate analysis, tumor capsule invasion, lymph node metastasis and distant metastasis were independent factors related to the positive expression of CK19 or MUC1 and the positive expressions of both CK19 and MUC1 (P < 0.05). There was a positive correlation between the expressions of CK19 and MUC1 (r = 0.628, P = 0.000).Conclusion:
The expressions of CK19 and MUC1 were significantly related to tumor capsule invasion, lymph node metastasis and distant metastasis of thyroid cancer, and these two biomarkers may be helpful to predict the blood micrometastasis and evaluate the prognosis.
Biblioteca responsable:
WPRO
Texto completo
Documentos relacionados